The team said that after clinical trials can be held it hopes to market the vaccine against so-called respiratory syncytial virus (RSV) in four or five years.
RSV, according to the Journal Lancet is long recognised as the major viral pathogen of the respiratory tract of infants and older adults.
Respiratory syncytial virus, or RSV, is very common, with infections occurring in 90 percent of children before their second birthday.